Press Release - October 12, 2004
Pheromone Sciences Retains AGORA Investor Relations
TORONTO, ONTARIO, October 12, 2004 -
Pheromone Sciences Corp. (TSX-V: PHS)
(http://www.pheromonesciences.com) is pleased
announce it has retained the services of AGORA
Relations Corp. ("AGORA")
provide investor relations, communications and
The objective of this agreement is to create effective communication between Pheromone, it's shareholders and the investment community through AGORA's powerful Internet based investor relations system. A customized and monitored on-line information & discussion centre will allow both the Company and AGORA to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications. Effective immediately, shareholders can access the on-line discussion and information centre by going to http://www.agoracom.com and selecting the "Pheromone Sciences" Information and Discussion Forum.
In addition, AGORA will be fully responsible for creating, implementing and executing an investor relations strategy, including the drafting of all materials, responding to investor queries via the web and e-mail and maintaining the Company's shareholder database. This consolidation of investor relations activities will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
Finally, Pheromone will gain significant amounts of exposure to potential new shareholders as a result of AGORA's targeted small-cap audience at both its own proprietary financial portal and that of The AOL Small-Cap Centre. AGORA is the exclusive provider of all small-cap content to The AOL Small-Cap Centre.
Christopher Neuman, President and CEO commented "Following the successful sale of our Fertility Monitor technology on August 31, 2004 and the receipt of immediate cash proceeds, we are returning to our original mandate of seeking new opportunities in biotechnology. Armed with this success, the time is now right to put a strong emphasis on investor relations for the purposes of communicating our current intentions to both our shareholders and the investment community. AGORA fulfils our need to manage and execute an IR strategy in a cost efficient manner, while providing the management team with the ability to focus on executing our business plan. Our shareholders will benefit from the ability to now ask questions and receive answers at anytime and from anywhere, while receiving real-time and equal access to information as it becomes available." Mr. Neuman went on to say "shareholders will be very happy to know that significant cost savings already implemented by AGORA will reduce the overall cost of engaging the firm by more than 80%. This is a win-win relationship for Pheromone"
For all future Pheromone Sciences investor relations needs, investors are asked to visit http://www.agoracom.com and select the "Pheromone Sciences" forum. Alternatively, investors are asked to e- mail all questions and correspondence to PHS@agoracom.com
The terms of the agreement are as follows: Duration - 12 months. Monthly Cash Compensation - $2,500.00. Stock Options - 250,000 shares at $.15, vesting equally every quarter over the term of the agreement with a one year hold period. This agreement has been negotiated entirely at arm's length. At the present time, no individual affiliated with AGORA beneficially owns, controls or directs any shares of Pheromone. However, depending on market conditions, individuals affiliated with AGORA may in the future acquire, dispose of and/or beneficially own, control or direct shares of Pheromone. AGORA is located in Toronto, Ontario.
About AGORA Investor Relations Corp. http://www.agoracom.com
AGORA Investor Relations Corp. (AGORA) is North America's first and only Investor Relations firm delivering two-way investor relations and communications solely through monitored discussion forums and e-mail. The digital delivery of investor relations allows AGORA to deliver an end-to-end solution to small-cap companies at savings of 50-80% while providing superior communications, audience reach and 100% transparency.
AGORA has specialized in small-cap investor relations since 1997 and has represented over 30 small- cap companies, with over 18 companies currently under contract. By leveraging the power of its' high- traffic financial portal, (www.agoracom.com), The AOL Small Cap Center (www.aol.ca), superior investor relations discussion forum and unique e-mail communication tools, Agora maximizes the resonance of clients' message and image.
About Pheromone Sciences Corp. http://www.pheromonesciences.com
Pheromone Sciences Corp. is a biotechnology research and development company seeking new opportunities to leverage its resources.
Christopher Neuman President and CEO (416) 861-9854 email@example.com http://www.pheromonesciences.com
AGORA Investor Relations http://www.agoracom.com (Select "Pheromone Sciences") PHS@agoracom.com
THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.
Press Releases from:2018 2017 2016 2015 2014 2013 2012
2011 2010 2009 2008 2007 2006 2005
2004 2003 2002 2001 2000 1999
2014, January 22
Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare CostsLink
2012, July 11
Sernova Corp. developing a tiered approach to the treatment of diabetes
Publisher: Canadian Investor Magazine
Author: Rochelle Emnance
2012, July 30
Feds back local diabetes discovery
Publisher: London Free Press
Author: Norman De Bono
2012, July 30
Federal program pumps $3 million into new, London business
Publisher: The London Free Press
Author: Norman De Bono
2010 July 10
Canada's economic action plan supports business innovators
Publisher: Federal Economic Development Agency for Southern OntarioLink
2007, February 20
"Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"
Author: Julie Ickes and James Finch
2006, October 04
"Sertoli Cells: Mother nature's anti-rejection drug"
Author: James Finch
2006, August 24
"Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"
Author: James Finch
Presentation and Video
May 03, 2018
March 29, 2018
2018 Financial Report - 1st Quarter
March 29, 2018
2018 Management Discussion & Analysis (MD&A) - 1st Quarter
December 11, 2017
Clearance by FDA of Sernova's US IND
Conference call audio recording
September 11, 2017
Sernova Fact Sheet
Subscribe to Sernova News
All Updates →